For Immediate Release: January 06, 2023 Today, the U.S. Food and Drug Administration approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease. Leqembi is the second…
BarbaraJanuary 12, 2023
According to this article published July 5, 2022 in the New York Times, there are behavioral changes that reduce dementia risk factors which are more effective than current available prescription…
BarbaraJuly 6, 2022
According to CMS plans announced Tuesday, the proposed CMS National Coverage Determination (NCD) would cover approved monoclonal antibodies targeting amyloid through coverage with evidence development (CED). To date, the only…
BarbaraJanuary 12, 2022
Five new on-demand webinars are available at no cost, and offer AMA PRA Category 1 Credits™. These webinars are focused at providing clinical staff tools to address the growing number…
BarbaraOctober 15, 2021
Aducanumab for Treatment of Alzheimer's Disease: Controversy & Patient Communications 1.5 CMA PRA Category 1 Credits This panel discussion among geriatric specialists will clarify controversial issues surrounding FDA's recent approval…
BarbaraAugust 23, 2021
Champions for Health Joins First Annual San Diego Gives Champions for Health is so excited to be part of San Diego Gives. This is the first annual day of giving…
Cody NelsonAugust 9, 2021
The mobile app, awarded a Top 10 in 2017 by MedApps, has been updated to include guidance for caregivers, including the addition of a caregiver burden assessment instrument. The app…
BarbaraJune 25, 2021
The latest edition (June 2021) of the Alzheimer's Guidelines for Screening, Evaluation & Management of Alzheimer's Disease & Related Dementias is now available for clinicians.
BarbaraJune 25, 2021
